vs

Side-by-side financial comparison of Canaan Inc. (CAN) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $11.0M, roughly 1.9× C4 Therapeutics, Inc.). Canaan Inc. runs the higher net margin — -18.4% vs -186.0%, a 167.5% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

CAN vs CCCC — Head-to-Head

Bigger by revenue
CAN
CAN
1.9× larger
CAN
$20.8M
$11.0M
CCCC
Higher net margin
CAN
CAN
167.5% more per $
CAN
-18.4%
-186.0%
CCCC

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CAN
CAN
CCCC
CCCC
Revenue
$20.8M
$11.0M
Net Profit
$-3.8M
$-20.5M
Gross Margin
99.9%
Operating Margin
-15.9%
-210.1%
Net Margin
-18.4%
-186.0%
Revenue YoY
112.8%
Net Profit YoY
40.7%
EPS (diluted)
$-0.05
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
CCCC
CCCC
Q4 25
$20.8M
$11.0M
Q3 25
$13.8M
$11.2M
Q2 25
$11.4M
$6.5M
Q1 25
$7.2M
Q4 24
$5.2M
Q3 24
$10.2M
$15.4M
Q2 24
$4.8M
$12.0M
Q1 24
$3.0M
Net Profit
CAN
CAN
CCCC
CCCC
Q4 25
$-3.8M
$-20.5M
Q3 25
$-1.5M
$-32.2M
Q2 25
$-11.9M
$-26.0M
Q1 25
$-26.3M
Q4 24
$-34.6M
Q3 24
$-10.4M
$-24.7M
Q2 24
$-5.4M
$-17.7M
Q1 24
$-28.4M
Gross Margin
CAN
CAN
CCCC
CCCC
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q1 25
Q4 24
Q3 24
99.9%
Q2 24
99.8%
Q1 24
Operating Margin
CAN
CAN
CCCC
CCCC
Q4 25
-15.9%
-210.1%
Q3 25
-27.0%
-306.4%
Q2 25
-45.5%
-441.0%
Q1 25
-402.9%
Q4 24
-728.4%
Q3 24
-77.2%
-183.9%
Q2 24
-193.9%
-178.6%
Q1 24
-1060.2%
Net Margin
CAN
CAN
CCCC
CCCC
Q4 25
-18.4%
-186.0%
Q3 25
-11.0%
-286.4%
Q2 25
-104.4%
-402.6%
Q1 25
-363.7%
Q4 24
-667.8%
Q3 24
-102.7%
-160.6%
Q2 24
-112.3%
-147.6%
Q1 24
-933.2%
EPS (diluted)
CAN
CAN
CCCC
CCCC
Q4 25
$-0.05
$-0.09
Q3 25
$-0.02
$-0.44
Q2 25
$-0.25
$-0.37
Q1 25
$-0.37
Q4 24
$-0.50
Q3 24
$-0.35
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$74.6M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$256.6M
Total Assets
$92.5M
$359.1M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
CCCC
CCCC
Q4 25
$74.6M
Q3 25
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Total Debt
CAN
CAN
CCCC
CCCC
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CAN
CAN
CCCC
CCCC
Q4 25
$52.4M
$256.6M
Q3 25
$44.7M
$154.4M
Q2 25
$33.8M
$174.1M
Q1 25
$195.1M
Q4 24
$216.0M
Q3 24
$43.6M
$242.7M
Q2 24
$56.8M
$247.1M
Q1 24
$258.3M
Total Assets
CAN
CAN
CCCC
CCCC
Q4 25
$92.5M
$359.1M
Q3 25
$81.7M
$265.5M
Q2 25
$78.0M
$296.5M
Q1 25
$319.5M
Q4 24
$349.6M
Q3 24
$69.3M
$376.1M
Q2 24
$73.7M
$381.1M
Q1 24
$398.4M
Debt / Equity
CAN
CAN
CCCC
CCCC
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
CCCC
CCCC
Operating Cash FlowLast quarter
$-22.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
CCCC
CCCC
Q4 25
$-22.1M
Q3 25
$-31.2M
Q2 25
$-12.1M
Q1 25
$-33.3M
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.0M
Q1 24
$-18.1M
Free Cash Flow
CAN
CAN
CCCC
CCCC
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CAN
CAN
CCCC
CCCC
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CAN
CAN
CCCC
CCCC
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons